ERSP RECOMMENDS EMERGENT HEALTH MODIFY, DISCONTINUE CERTAIN ADVERTISING CLAIMS FOR ‘JDI MULTIVITAMIN’ Marketer Voluntarily Modified Certain Claims

New York, NY – Dec. 14, 2011 – The Electronic Retailing Self-Regulation Program (ERSP) has

recommended that Emergent Health Corp., modify or discontinue certain Internet

advertising claims for the company’s  “JDI MultiVitamin,” promoted by the advertiser as

designed to “increase adult stem cells.” The marketer voluntarily modified several claims at

issue in ERSP’s inquiry.

ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by the

Council of Better Business Bureaus (CBBB) with policy oversight by the National Advertising

Review Council (NARC).

The marketer’s advertising came to the attention of ERSP pursuant to an anonymous

competitive challenge.

Claims at issue in ERSP’s review included:

  • “It is designed to supply all of the micro nutrients needed to support life as well as

increase adult stem cells.”

  • Immune System Support, More Energy, More Stamina, Clearer Thinking, Maintain

Health, Just Plain Feeling Better”

  • “… may also help maintain existing telomere length by up to 5% according to recent

studies of multi vitamins.”

  • “The ingredients of the product have been thoroughly tested for safety and also

studied for the effects of increasing adult stem cells, improving immune system

support, decreasing inflammation and bettering mental acuity and mood as well as

telomere support based upon structure and function.”

  • “My grandmother has Alzheimer’s, osteo, and heart problems. At her last doctor’s

visit he told her that her tests are better than they have been for over 20 years.”

B.C.

JDI MultiVitamin is a dietary supplement containing a number of essential vitamins and

minerals. According to the marketer, the supplement’s proprietary formula is also designed

to “increase adult stem cells.”

At the outset of ERSP’s inquiry, the marketer asserted that it had voluntarily modified or

discontinued certain of the claims at issue. While  confirming that Emergent Health had

implemented changes, ERSP noted in it decision that it remained concerned with several

core claims. ERSP further noted that the advertiser did not provide ERSP with the results of

testing on the JDI MultiVitamin formula, but instead relied on studies of the product’s

ingredients.

Following its review, ERSP determined that the evidence in the record did not support claims

that the use of the product would increase the number of adult stem cells, thereby

improving immune system support, decreasing inflammation or bettering mental acuity and

mood. ERSP recommended Emergent Health discontinue  claims that the product can

increase the number stem cells and/or provide specific disease protection. 2

ERSP also was concerned about statements that could be reasonably interpreted as

unqualified superiority claims (e.g., “The most simple and cost effective…”  and “the most

advanced…”). Emergent Health informed ERSP that it has modified these claims to appear in

future advertising in a non-comparative context.

Regarding the consumer testimonials at issue, ERSP  noted that consumer endorsements

themselves are not competent and reliable scientific evidence and a marketer should

possess reliable substantiation – including, when appropriate, competent and reliable

scientific evidence – to support such in the same manner the marketer would be required to

do if it had made the representation directly. In the absence of data supporting the results

consumers can typically expect, ERSP recommended that the marketer refrain from using

consumer testimonials to communicate atypical product performance.

The company, in its marketer’s statement, said it “…agrees to accept ERSP’s report as

applicable and agrees to amend all statements in its advertising to meet the conclusion of

the ERSP report. Likewise, the Company is willing to complete the process and take ERSP’s

recommendations into consideration in its future advertising.”

 

ERSP’s inquiry was conducted under ERSP Policies and Procedures for the Electronic Retailing Self-Regulation Program. Details of the initial inquiry, ERSP’s decision, and the advertiser’s response are available at the NARC Website, www.narcpartners.org

About Advertising Industry Self-Regulation:

The National Advertising Review Council (NARC) was formed in 1971. NARC establishes the policies and procedures for the National Advertising Division (NAD) of the Council of Better Business Bureaus, the CBBB’s Children’s Advertising Review Unit (CARU), the National Advertising Review Board (NARB) and the Electronic Retailing Self-Regulation Program (ERSP).

The NARC Board of Directors is composed of representatives of the 4A’s (American Association of Advertising Agencies, Inc.) the American Advertising Federation, Inc. (AAF), the Association of National Advertisers, Inc. (ANA), Council of Better Business Bureaus, Inc. (CBBB), Direct Marketing Association (DMA), Electronic Retailing Association (ERA) and Interactive Advertising Bureau (IAB).  Its purpose is to foster truth and accuracy in national advertising through voluntary self-regulation.

NAD, CARU and ERSP are the investigative arms of the advertising industry’s voluntary self-regulation program. Their casework results from competitive challenges  from other advertisers, and also from self-monitoring traditional and new media. NARB, the appeals body, is a peer group from which ad-hoc panels are selected to adjudicate NAD/CARU cases that are not resolved at the NAD/CARU level. This unique, self-regulatory system is funded entirely by the business community; CARU is  financed by the children’s advertising industry, while NAD/NARC/NARB’s primary source of funding is derived from membership fees paid to the CBBB. ERSP’s funding is primarily derived from membership in the Electronic Retailing Association. For more information about advertising industry self-regulation, please visit www.narcpartners.org.